Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Brain Neoplasms 2 Neoplasm, Residual 1 NSCLC 1 Liver Neoplasms 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Hepatocellular 1

Interventions

Gefitinib 5 icotinib 4 Pemetrexed 4 Docetaxel 4 camrelizumab 3 apatinib 3 anlotinib 3 aflutinib 3 Erlotinib Hydrochloride 3 osimertinib 2 dacomitinib 2 Thalidomide 2 Radiosurgery 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 trilaciclib 1 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 famitinib 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiofrequency Ablation 1 Microphysiological Systems 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × NSCLC × Tyrosine Kinase Inhibitors × Clear all

NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡